Apexigen Inc. (NASDAQ: APGN) stock jumped 45.03% on Wednesday to $0.58 against a previous-day closing price of $0.40. With 10.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.27 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6280 whereas the lowest price it dropped to was $0.4902. The 52-week range on APGN shows that it touched its highest point at $31.35 and its lowest point at $0.33 during that stretch. It currently has a 1-year price target of $3.20.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APGN was up-trending over the past week, with a rise of 52.96%, but this was up by 27.41% over a month. Three-month performance dropped to -57.06% while six-month performance fell -68.32%. The stock lost -94.27% in the past year, while it has lost -15.00% so far this year. A look at the trailing 12-month EPS for APGN yields -1.50 with Next year EPS estimates of -0.69. For the next quarter, that number is -0.10. This implies an EPS growth rate of -5.00% for this year and 18.80% for next year.
Float and Shares Shorts:
At present, 22.65 million APGN shares are outstanding with a float of 20.83 million shares on hand for trading. On Apr 27, 2023, short shares totaled 0.14 million, which was 0.56% higher than short shares on Mar 30, 2023. In addition to Dr. Xiaodong Yang M.D., Ph.D. as the firm’s CEO & Director, Mr. Francis W. Sarena serves as its Pres & COO.
Through their ownership of 12.84% of APGN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.94% of APGN, in contrast to 3.13% held by mutual funds. Shares owned by individuals account for 1.73%. As the largest shareholder in APGN with 5.33% of the stake, Arcadia Securities LLC holds 1,314,479 shares worth 1,314,479. A second-largest stockholder of APGN, The Vanguard Group, Inc., holds 253,880 shares, controlling over 1.03% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in APGN, holding 213,833 shares or 0.87% stake. With a 1.03% stake in APGN, the Vanguard Extended Market Index Fu is the largest stakeholder. A total of 253,880 shares are owned by the mutual fund manager. The Fidelity Extended Market Index Fu, which owns about 0.37% of APGN stock, is the second-largest Mutual Fund holder. It holds 91,283 shares valued at 44364.0. Fidelity Total Market Index Fund holds 0.13% of the stake in APGN, owning 31,169 shares worth 15148.0.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, APGN reported revenue of $0.00 and operating income of -$1.78B. The EBITDA in the recently reported quarter was -$1.78B and diluted EPS was -$241.21.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APGN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With APGN analysts setting a high price target of $9.00 and a low target of $0.64, the average target price over the next 12 months is $4.88. Based on these targets, APGN could surge 1451.72% to reach the target high and rise by 10.34% to reach the target low. Reaching the average price target will result in a growth of 741.38% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.